TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: SQ
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Risk of first ischemic stroke
Endpoint domain: Mortality/survival
Primary endpoint: child HEI-2010 score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: GEDV values for monitoring cardiac preload
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Risk of developing prostate cancer
Endpoint domain: Mortality/survival
Primary endpoint: Mean static and moving 2-point discrimination
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of ST (Stent Thrombosis)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Systolic blood pressure (SBP) as a predictor of CVD events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: maximum flow rate (Qmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Apnea-hypopnea index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average oxyhemoglobin saturation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean LFM measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reduction in nasal symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reversible blood lymphocyte reductions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: delayed wound healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: postprandial glycemic excursion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: frailty score change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Two-year survival
Endpoint domain: Mortality/survival
Primary endpoint: Two-year failure-free survival (FFS)
Endpoint domain: Mortality/survival
Primary endpoint: mood symptoms improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mental HRQoL improvement
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: MPQ percentage difference scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual analog scale for postoperative pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of the second stage of labor
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual Analog Scale score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Wear in total 3D direction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: favorable outcome at 12 months
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: CF-related inpatient PMPM costs
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Total healthcare costs
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: pre-bypass temperature
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intracranial hemorrhage rates
Endpoint domain: Adverse events/effects
Primary endpoint: Average concentration of PTH
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: TBR10 and TBR120 medians
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic confidence for PE detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Assessability of anatomical structures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: proximal head penetration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: 3D penetration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: levels of urinary 8‐hydroxy‐deoxyguanosine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: total reactive oxygen species
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serum levels of high sensitivity C reactive protein
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: serum levels of interleukin (IL)‐6
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: serum levels of IL‐8
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Improvement in skin dryness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Improvement in itchiness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Decrease in dermal medication usage
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Rate of admission for psychotic disorders
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Rate of employment
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Detection rate for clinically significant cancers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Overall lesion visualization and characterization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: modified Rankin Scale ≤2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: quality-adjusted-days
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: SF36 score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: verbal learning decline
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: objective hot flashes reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Discharge home the day of procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of visible AKs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Prevalence of NMSCs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Incidence of NMSCs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: decoding skills
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in forgiveness
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Reduction in anger
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Illness perceptions
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Quality-adjusted survival
Endpoint domain: Mortality/survival
Primary endpoint: Crude survival
Endpoint domain: Mortality/survival
Primary endpoint: Health-care resource use
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: SS (Spherical Equivalent)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum creatinine level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: PTRA success rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response time for LMQs and OEQs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Speed of interpreting maternal behaviour
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in glycated hemoglobin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Weight gain from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Activation of the parietal cortex in response to highly desirable food images
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall satisfaction with HCGM
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Communication clarity
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Integration into workflow
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: %BF (Body Fat Percentage)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: CRF (Cardiorespiratory Fitness)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ThRR increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: MAP increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Overall survival at 1 year
Endpoint domain: Mortality/survival
Primary endpoint: Complete and partial response rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Local recurrence-free survival
Endpoint domain: Mortality/survival
Primary endpoint: intraoperative pain scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of treatment directed by blood culture results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of MCs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neck pain
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Disabling arm pain
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Radiologic degeneration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functional water seals in latrines
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percentage change in body mass loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Z-scores of BMC at total body
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Z-scores of BMC at femoral neck
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Z-scores of BMC at total hip
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: children's energy intake from the entrée
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: total lunch energy intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Total protein level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: changes in knowledge and beliefs
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: WHO well-being index
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Total risk scores of psychosocial risk factors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of postoperative atrial fibrillation (POAF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Energy intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in dietary intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Detection of endoleaks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Graft limb thrombosis identification
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mortality due to hemorrhagic shock
Endpoint domain: Mortality/survival
Primary endpoint: Glycemic control (HbA1c values)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Diabetes-related knowledge
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Rate of injurious falls
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: personal relevance
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: effectiveness
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: credibility
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Incidence of symptomatic hypoglycaemia
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of skin reaction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Effective rate for grade III dermal injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Wound-healing time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: mean percentage inhibition of serum thromboxane B2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: mean percentage inhibition of platelet aggregation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Time to reach maximum concentration (tmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total control of symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Partial control of symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Muscle tone improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Passive ankle dorsiflexion range improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gross motor function improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in plaque area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in vitality of supragingival plaque
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hip circumference reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: EPDS scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Percentage of patients reaching goal low density lipoprotein cholesterol levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: User satisfaction with condom types
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Preference for male condom over female condom
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Satisfaction with antenatal and birth care
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Preparedness for birth
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Preparedness for the time after the baby's birth
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: abstinence motivation
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: substance use reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC(0‐∞) for talinolol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: C(max) for talinolol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma concentration-time profiles
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Half-life (t(1/2)) of meloxicam
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: light depth of anesthesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: hemodynamic changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: postoperative pain relief
Endpoint domain: Adverse events/effects
Primary endpoint: Adverse events including death
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction in CES-D scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: incision length
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: visual analogue pain scale (VAS) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum parathyroid hormone levels (S. PTH)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Severity of clinical and skeletal fluorosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in inspiratory function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Global Rating of Change (GRC) score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Incidence of hypophysitis
Endpoint domain: Adverse events/effects
Primary endpoint: Corticotroph deficiency at follow-up
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Recovery of thyrotroph and gonadotroph functions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Risk of H1N1 infection
Endpoint domain: Mortality/survival
Primary endpoint: Normalization of abnormal psychometry
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: P300ERP improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Venous ammonia levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Relative mean AL reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of sites exhibiting BOP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effect clearances (CL(miosis))
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of ptosis at 90 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean time from induction to delivery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Concentration of D-dimer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Concentration of plasminogen activator inhibitor type-1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Blood loss during surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: No pain at 52 weeks
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: minimum lumen area
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: recurrent in‐stent neointimal hyperplasia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: 2-year rate of ischemic stroke
Endpoint domain: Adverse events/effects
Primary endpoint: Time to recognition of respiratory or cardiac arrest
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Time to start of ventilatory maneuvers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Time to start of chest compressions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reduction in anger symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Cerebral Blood Flow (CBF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Brain volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Glare sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: tissue stiffness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum TG incremental area under the curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Diagnostic yield of EBUS-TBNA for sarcoidosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Colour change in enamel
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Resin tag length
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in incontinence episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean adjusted growth rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serum cortisol concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Overall incidence of treatment-emergent adverse events (TEAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Net cost of team-based primary care
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: simple sum score of remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ConRew score of remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in eating disorder symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in positive self-schemas
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Deep venous thrombosis rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Venous thromboembolism rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Colonic compliance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Fasting colonic tone
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes